WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising a peptide comprising SEQ ID NO:4, wherein the pH of the composition is about 8.1.

2. A pharmaceutical composition comprising a peptide comprising SEQ ID NO:4 and sorbitol.

3. A pharmaceutical composition comprising a peptide comprising SEQ ID NO:4 and meta-cresol.

4. The pharmaceutical composition of claim 2 or 3, wherein the pH of the composition is at least 7.9.

5. The pharmaceutical composition of claim 2 or 3, wherein the pH of the composition is about 7.9 to about 8.4, optionally wherein the pH of the composition is about 8.1.

6. The pharmaceutical composition of any one of claims 1-3, wherein the composition comprises a pH-adjusting agent.

7. The pharmaceutical composition of any one of claims 1-3, wherein the composition comprises sodium hydroxide.

8. The pharmaceutical composition of claim 2 or 3, wherein the composition comprises sodium hydroxide at a concentration sufficient to make the pH of the composition at least 7.9.

9. The pharmaceutical composition of claim 2 or 3, wherein the composition comprises sodium hydroxide at a concentration sufficient to make the pH of the composition about 7.9 to about 8.4, optionally about 8.1.

10. The pharmaceutical composition of any one of claims 1 or 3-9, wherein the composition comprises a tonicity agent.

11. The pharmaceutical composition of claim 10, wherein the tonicity agent is sorbitol, mannitol, or propylene glycol.

12. The pharmaceutical composition of claim 2 or 11, wherein the concentration of sorbitol is about 190 mM to about 250 mM.

13. The pharmaceutical composition of claim 12, wherein the concentration of sorbitol is about 220 mM, optionally wherein the concentration is 220.3 mM.

14. The pharmaceutical composition of claim 2 or 11, wherein the concentration of sorbitol is about 35 mg/mL to about 45 mg/mL.

15. The pharmaceutical composition of claim 14, wherein the concentration of sorbitol is about 40 mg/mL to about 41 mg/mL, optionally wherein the concentration is 40.13 mg/mL.

16. The pharmaceutical composition of any one of claims 1, 2, or 4-14, wherein the composition comprises an antimicrobial agent, optionally wherein the antimicrobial agent is meta-cresol or phenol.

17. The pharmaceutical composition of claim 3 or 16, wherein the concentration of meta-cresol is about 0.27% w/v to about 0.45% w/v or wherein the concentration of meta-cresol is about 25 mM to about 30 mM.

18. The pharmaceutical composition of claim 17, wherein the concentration of meta-cresol is about 0.31% w/v or wherein the concentration of meta-cresol is about 28.6 mM.

19. The pharmaceutical composition of claim 3 or 16, wherein the concentration of meta-cresol is about 2.7 mg/ml to about 4.5 mg/ml.

20. The pharmaceutical composition of claim 3 or 19, wherein the concentration of meta-cresol is about 3.1 mg/ml.

21. The pharmaceutical composition of any one of claims 1-20, wherein the composition comprises a buffer, optionally wherein the buffer is sodium phosphate or TRIS.

22. The pharmaceutical composition of claim 21, wherein the concentration of sodium phosphate is about 5 mM to about 25 mM.

23. The pharmaceutical composition of claim 22, wherein the concentration of sodium phosphate is about 20 mM, optionally wherein the concentration is 20 mM or 20.1 mM.

24. The pharmaceutical composition of any one of claims 21-23, wherein the sodium phosphate comprises sodium phosphate monobasic monohydrate and sodium phosphate dibasic heptahydrate.

25. The pharmaceutical composition of claim 24, wherein the concentration of sodium phosphate monobasic monohydrate is about 1 mM, and wherein the concentration of sodium phosphate dibasic heptahydrate is about 19 mM, optionally 19 mM or 19.1 mM.

26. The pharmaceutical composition of claim 22, wherein the concentration of sodium phosphate is about 10 mM.

27. The pharmaceutical composition of claim 26, wherein the sodium phosphate is sodium phosphate dibasic heptahydrate.

28. The pharmaceutical composition of claim 21, wherein the concentration of sodium phosphate is about 1 mg/mL to about 10 mg/mL.

29. The pharmaceutical composition of claim 28, wherein the concentration of sodium phosphate is about 5.25 mg/mL

30. The pharmaceutical composition of any one of claims 21, 28, and 29, wherein the sodium phosphate comprises sodium phosphate monobasic monohydrate and sodium phosphate dibasic heptahydrate.

31. The pharmaceutical composition of claim 30, wherein the concentration of sodium phosphate monobasic monohydrate is about 0.13 mg/mL and the concentration of sodium phosphate dibasic heptahydrate is about 5.12 mg/mL.

32. The pharmaceutical composition of claim 28, wherein the concentration of sodium phosphate is about 2.68 mg/mL.

33. The pharmaceutical composition of claim 32, wherein the sodium phosphate is sodium phosphate dibasic heptahydrate.

34. The pharmaceutical composition of any one of claims 1-33, wherein the concentration of the peptide comprising SEQ ID NO:4 is about 0.5 mg/mL to about 5 mg/mL.

35. The pharmaceutical composition of claim 34, wherein the concentration of the peptide comprising SEQ ID NO:4 is about 1 mg/mL.

36. The pharmaceutical composition of claim 34, wherein the concentration of the peptide comprising SEQ ID NO:4 is about 2 mg/mL.

37. The pharmaceutical composition of claim 34, wherein the concentration of the peptide comprising SEQ ID NO:4 is about 5 mg/mL.

38. A pharmaceutical composition comprising about 0.5 mg/mL to about 5 mg/mL of a peptide comprising SEQ ID NO:4, about 190 mM to about 250 mM sorbitol, about 5 mM to about 25 mM sodium phosphate, and about 0.27% w/v to about 0.45% w/v meta-cresol, and wherein the pH of the pharmaceutical composition is about 7.9 to about 8.4.

39. A pharmaceutical composition comprising about 0.5 mg/mL to about 5 mg/mL of a peptide comprising SEQ ID NO:4, about 220.3 mM sorbitol, about 20.1 mM sodium phosphate, and about 0.31% w/v meta-cresol, and wherein the pH of the pharmaceutical composition is about 8.1.

40. A pharmaceutical composition comprising about 0.5 mg/mL to about 5 mg/mL of a peptide comprising SEQ ID NO:4, about 220.3 mM sorbitol, about 20 mM sodium phosphate, and about 0.31% w/v meta-cresol, and wherein the pH of the pharmaceutical composition is about 8.1.

41. The pharmaceutical composition of claim 39 or 40, wherein the sodium phosphate comprises sodium phosphate monobasic monohydrate and sodium phosphate dibasic heptahydrate.

42. A pharmaceutical composition comprising about 0.5 mg/mL to about 5 mg/mL of a peptide comprising SEQ ID NO:4, about 220.3 mM sorbitol, about 10 mM sodium phosphate, and about 0.31% w/v meta-cresol, and wherein the pH of the pharmaceutical composition is about 8.1.

43. The pharmaceutical composition of claim 42, wherein the sodium phosphate is sodium phosphate dibasic heptahydrate.

44. The pharmaceutical composition of any one of claims 38-43 comprising sodium hydroxide.

45. The pharmaceutical composition of any one of claims 38-44 comprising about 1 mg/mL of the peptide comprising SEQ ID NO:4.

46. The pharmaceutical composition of any one of claims 38-44 comprising about 2 mg/mL of the peptide comprising SEQ ID NO:4.

47. The pharmaceutical composition of any one of claims 38-44 comprising about 5 mg/mL of the peptide comprising SEQ ID NO:4.

48. The pharmaceutical composition of any one of claims 1-47, wherein the composition is liquid.

49. The pharmaceutical composition of any one of claims 1-48, wherein the composition is for parenteral administration.

50. The pharmaceutical composition of any one of claims 1-49, wherein the composition is for subcutaneous administration.

51. A syringe, vial, or a pen comprising the pharmaceutical composition of any one of claims 1-50, optionally wherein the syringe, vial, or pen is a multi-dose syringe, vile, or pen.

52. Use of ~~A method of treating Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) comprising administering to a human subject in need thereof~~ the pharmaceutical composition of any one of claims 1-50 in the manufacture of a medicament for treating Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD), wherein the medicament is to be administered to a human subject in need thereof.

53. Use of ~~A method of reducing liver fat comprising administering to a human subject in need thereof~~ the pharmaceutical composition of any one of claims 1-50 in the manufacture of a

medicament for reducing liver fat, wherein the medicament is to be administered to a human subject in need thereof.

54. Use of ~~A method of treating type 2 diabetes mellitus comprising administering to a human in need thereof~~ the pharmaceutical composition of any one of claims 1-50 in the manufacture of a medicament for treating type 2 diabetes mellitus, wherein the medicament is to be administered to a human in need thereof.

55. The use ~~method~~ of any one of claims 52-54, wherein the peptide is to be administered daily, optionally wherein the peptide is to be administered once daily.

56. The use ~~method~~ of any one of claims 52-55, wherein the peptide is to be administered by injection, optionally wherein the injection is subcutaneous.

57. The use ~~method~~ of any one of claims 52-56, wherein the peptide is to be administered ~~administration is an~~ adjunct to diet and exercise.